TRP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. TRP is in a strong uptrend, but it’s stretched short-term (RSI_6 ~75.7) and trading near resistance (R1 58.724 already reclaimed post-market; next ceiling R2 ~60.069). With momentum still positive but slowing (MACD histogram positive and contracting) and pattern stats pointing to a slightly negative next-day move, the risk/reward for an immediate entry is unfavorable. Prefer a pullback toward the ~56.55 pivot (or lower) before buying; otherwise, hold rather than chase.
Trend is bullish: SMA_5 > SMA_20 > SMA_200 confirms an established uptrend. However, the stock looks short-term overextended: RSI_6 at 75.687 signals overbought conditions (despite the label, this is typically ‘overbought’ territory on a fast RSI). MACD remains above zero (bullish), but the histogram is positively contracting, suggesting upside momentum is decelerating. Price levels: Pivot 56.546 is the key ‘fair value’ reversion area; immediate resistance was R1 58.724 (now exceeded post-market at ~59.04) with next resistance at R2 60.069—meaning upside from here is nearer a ceiling than support. Support levels: S1 54.369 then S2 53.024. Short-term pattern model: ~70% chance of -1.36% next day, +3.38% next week, -2.49% next month—supports a near-term dip risk even within a broader constructive tape.
Intellectia Proprietary Trading Signals
Analyst sentiment is constructive with multiple firms maintaining/initiating bullish stances and nudging targets higher (recent raises from JPMorgan and Morgan Stanley). The company previously communicated a multi-year outlook/visibility (per prior analyst commentary), which supports longer-duration infrastructure-style investing. Upcoming earnings on 2026-02-13 (pre-market) can be a catalyst if results/guidance beat expectations (consensus EPS est. ~0.67).
increases probability of a near-term pullback. Options tape shows defensive near-term flow (high put/call volume). Earnings on 2026-02-13 is an event risk (gap risk) given recent EPS/net income weakness in the latest reported quarter.
Latest reported quarter: 2025/Q3. Revenue grew to 3.704B (+10.30% YoY), and gross margin improved to 50 (+3.58% YoY), indicating top-line growth and margin resilience. However, profitability deteriorated sharply: net income fell to 609M (-58.20% YoY) and EPS dropped to 0.59 (-57.86% YoY). The mixed picture (good revenue/margins, weak bottom line) supports a stable business narrative but raises questions on near-term earnings quality and the durability of per-share growth until profitability re-accelerates.
Recent trend: predominantly positive. Since early Nov 2025, multiple upgrades/Outperform/Buy reiterations occurred (BMO upgrade to Outperform; CIBC upgrade to Outperformer; RBC/Scotia/TD constructive), and more recently (Jan 2026) Morgan Stanley and JPMorgan both raised price targets while keeping Overweight. Wall Street pros: improving multi-year outlook visibility and execution narrative, and broad-based target raises. Cons: at least one large firm remains Neutral (Citi), and the fundamental headline from the latest quarter shows significant YoY EPS/net income compression, which can cap upside if it persists. Influential/political flows: no recent congress trading data available; hedge funds and insiders show neutral activity trends.
